Pascal Touchon, President & CEO, Atara Biotherapeutics, San Francisco, CA, describes the pipeline of Atara Biotherapeutics including the ATA3219, an anti-CD19 allogeneic T-cell immunotherapy targeting B-cell malignancies, as well as ATA3271, a chimeric antigen receptor (CAR) T-cell therapy targeting mesothelin for solid tumors. He additionally discusses the latest results from the Phase I/II EMBOLD study (NCT03283826) of ATA188, a T-cell immunotherapy that targets Epstein-Barr virus (EBV) in patients with progressive multiple sclerosis. This interview took place at Meeting on the Mesa 2021.